Colin Rom

Partner, Head of Public Policy for Bio + Health


Andreessen Horowitz

Colin Rom is a partner and the Head of Public Policy for Bio+Health at Andreessen Horowitz.

Prior to joining a16z, Colin was the Managing Director of Science and Innovation Policy at Mayo Clinic, leading federal engagement strategy and policy creation in areas including artificial intelligence, emerging biotechnology, and care delivery modernization. Before Mayo, Colin spent two years as a senior advisor to the Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA), leading several agency-wide initiatives and serving as a liaison between the FDA and White House Coronavirus Task Force during the first year of federal COVID-19 response. He also spent one year at the White House Office of Management and Budget as a policy and political advisor to the Health Program Associate Director and five years as a health policy advisor in the United States Senate, working for Senator Richard Burr (N.C.) and the Senate Committee on Health, Education, Labor, and Pensions.

Colin graduated from the University of Mary Washington and is completing an M.S. in Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University.


    3:30 PM - 4:00 PM

    Wednesday November 15, 2023

    Legislative and Regulatory Landscape Facing Telehealth, Artificial Intelligence, and Interoperability Adoption

    • How CMS views consumerization as they make decisions on reimbursement for RPM and RTM technologies and understanding the regulatory process for SaMD at FDA and the next steps
    • What to know about the recent Executive Order put out by the White House, and the recent HHS/ONC rule on interoperability.
    • How Congress is wrestling with how to deal with PBM’s and digital health investment treants
    12:30 PM - 1:15 PM

    Thursday August 25, 2022

    Regulatory Landscape Facing Telehealth Innovation and Coverage

    • An overview of Mayo Clinic investment and patient/provider experience in Acute Care at Home model and digital/remote health
    • Leveraging remote monitoring and Software as medical device (SaMD) products
    • Understanding the regulatory process for SaMD at FDA and next steps
    • A look at the future of telehealth policy at HHS and CMS reimbursement on telehealth, focusing on how the PHE impacts telehealth coverage and reimbursement
    • How CMS views consumerization as they make decisions on reimbursement for RPM and RTM technologies
    • How leaders within HHS/CMS view the continual shift from FFS to VBC
    View Full Agenda